메디톡스 (사진=메디톡스)

[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox will launch a lawsuit against Hugel for botulinum toxin strains following Daewoong Pharmaceutical. 

 

This is because the U.S. International Trade Commission (ITC) refused to accept Hugel's request to end the lawsuit.

The ITC released the lawyer's opinion on the official website on the 22nd (local time) in charge of the lawsuit between Medytox and Hugel.

The ITC lawsuit between Medytox and Hugel is expected to begin in earnest. According to the schedule released by ITC, the preliminary ruling is in January 2024. The final ruling is in May 2024 and will take effect two months later.

In October last year, Hugel applied to the U.S. Food and Drug Administration (FDA) for an item license for the botulinum toxin drug "Botulinum" (export name Retivo) as an indication for improving wrinkles in the forehead. 

 

Approval is expected for the second quarter of this year. There is also a possibility that the ITC lawsuit will affect FDA approval. An official from Hugel said, "As there are no products that have been approved for items in the U.S., the issue is different from previous cases of lawsuits." This means that we have to wait and see the court's ruling.

Hugel's domestic market share of botulinum toxin is estimated to be around 40%. I was ahead of Medytox, which is around 30%. Industry sources say that the domestic market will also be significantly affected by the outcome of the ITC lawsuit. If Medytox wins the ITC lawsuit, it is likely to expand in Korea.

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]